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Many glomerular diseases, including IgA nephropathy, mem-
branoproliferative glomerulonephritis (GN), variants of idio-
pathic focal sclerosis, and lupus nephritis are characterized by
mesangial cell proliferation. There is increasing evidence that
mesangial cell proliferation in GN may not be a benign process,
but may be associated with activation of the mesangial cell, as
reflected by the acquisition of a smooth muscle cell-like pheno-
type [1] and by the synthesis and secretion of increased
amounts of normal and abnormal mesangial matrix components
[21 and proteinases (David Lovett, manuscript submitted).
Thus, an understanding of the mechanisms that initiate and
maintain the proliferative response in active GN may provide
useful insights into future therapeutic strategies of these dis-
eases.
Mediators of mesangial cell proliferation in GN
Mesangial cells in culture will proliferate in response to
numerous growth factors (Table 1) [3—101. However, little
information is available as to the type, relative importance, and
cellular source of the growth factors involved in mesangial cell
proliferation in vivo in glomerular diseases.
The most likely cellular candidates for releasing growth
factors within the glomerulus would include infiltrating platelets
and monocyte-macrophages, and endogenous glomerular cells
(especially the glomerular endothelial and mesangial cell) (Ta-
ble 2). At the present time, very little information is available as
to the growth factors produced by glomerular epithelial cells.
Platelets
The mitogenic activity of serum is largely derived from
factors released by platelets during clotting. Platelets contain
numerous growth factors, including platelet-derived growth
factor (PDGF), an EGF/TGF-cx like factor, TGF-/3, IGF-l, a
hepatocyte growth factor (HGF), and a platelet-derived endo-
thelial cell growth factor (PD-ECGF) [10—14]. Activated plate-
lets also express interleukin-l (IL-l) on their surface [15]. Thus,
it is not surprising that platelet releasates and lysates can
stimulate proliferation of rat and rabbit mesangial cells in
culture [16, 171.
There is also increasing evidence to support a role for
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platelets in mediating glomerular cell proliferation in vivo.
Many experimentally-induced glomerular diseases that result in
glomerular cell proliferation are characterized by an initial
injury to the glomerular endothelium or mesangium [18—23]. In
many of these diseases, an influx of platelets into glomeruli can
be demonstrated at the time of the cellular injury [18—20, 23,
241. For example, in the rat model of glomerular injury induced
with oxidants generated by neutrophil myeloperoxidase and its
substrates, hydrogen peroxide and halides, a pronounced en-
dothelial cell injury with massive intraglomerular platelet accu-
mulation can be demonstrated within minutes, and is followed
by an impressive proliferation of glomerular cells [24].
An influx of platelets into glomeruli can also be demonstrated
in a rat model of subendothelial immune complex nephritis
(induced by the renal artery perfusion of concanavalin A and
anti-concavalin A antibody) that histologically resembles dif-
fuse proliferative lupus nephritis [25]. By electron microscopy,
the platelets can be shown to be activated, and many are
degranulated and adherent to areas of the glomerular basement
membrane where the endothelium has been denuded (Fig. 1). A
marked proliferation of glomerular endothelial and mesangial
cells occurs in the initial days following the platelet influx (Fig.
2), eventually resulting in a markedly hypercellular lesion.
Consistent with these observations, Clark et al have shown that
an increased renal uptake of platelets occurs in diffuse prolifer-
ative lupus nephritis in humans [26].
The first evidence that the association of intraglomerular
platelet accumulation with subsequent glomerular cell prolifer-
ation represented a cause and effect relationship was provided
by Cattell in the experimental model of glomerular injury
induced with Habu snake venom [27]. In this model, the
intravenous injection of Habu snake venom results in injury to
only a minority of glomeruli, and is characterized by an acute
dissolution of the mesangium with loss of mesangial cells
("mesangiolysis") followed by mesangial cell proliferation [20].
Platelets and platelet aggregates are frequent in the areas of
mesangiolysis [20]. When rats were rendered thrombocytopenic
with an anti-platelet serum prior to injection of venom, the rats
still developed the acute mesangiolysis, but the subsequent
mesangial cell hypercellularity was largely prevented [27].
Treatment of rats with the anti-platelet agents, dipyridamole
[281 or sulindac [29], have also been reported to reduce the
mesangial cell hypercellularity in this model, whereas aspirin
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Table 1. Peptide growth factors capable of inducing mesangial cell
proliferation in vitro
Platelet derived growth factor (PDGF)
Interleukins I and 6 (IL-I, IL-6)
Tumor necrosis factor alpha (TNF-a)
Epidermal growth factor (EGF)
Endothelin
Insulin-like growth factor I (IGF-l)
Basic fibroblast growth factor (bFGF)
Transforming growth factor alpha (TGF-a)
Insulin
Arginine-vasopressin
Transforming growth factor beta (TGF,3)a
At low concentrations (0.01 to 0.1 ng/ml) TGF-J3 potentiates the
proliferative response of human mesangial cells to EGF or TGF-a [8].
TGF-/3 also induces proliferation in mouse mesangial cells at confluence
[91.
Table 2. Growth factors present in various cell populations that may
have a role in glomerulonephritis
Infiltrating cells Glomerular cells
Mesangial EndothelialaPlatelets Macrophages
PDGF PDGF PDGF PDGF
EGF/TGF-a IL-l IL-I bFGF
PD-ECGF TNF lL-6 IL-6
TGF-/3 IL-6 TNF IL-I




a With the exception of PDGF, the growth factors listed are based on
studies of enbdothelial cells from other sites.
was not protective [28]. Unfortunately, studies utilizing aspirin
are complicated by the fact that this agent does not block
platelet adherence to collagen or its subsequent release reaction
[30, 31].
We have investigated the role of platelets in another model of
mesangial proliferative nephritis which is induced with an
antibody to the Thy 1.1 antigen that is present on the rat
mesangial cell membrane [32]. This model is also associated
with an acute mesangiolysis and platelet influx followed by
mesangial cell proliferation [23]. As in the Habu snake venom
model, depletion of platelets with an anti-platelet antibody
significantly reduces glomerular cell proliferation without any
demonstrable effect on mesangiolysis [32]. In contrast, comple-
ment depletion (with cobra venom factor) prevents both the
mesangiolysis (and platelet influx) and the secondary prolifera-
tive response [23, 33].
Macrophages
Monocyte-macrophages can be demonstrated in glomeruli in
many types of GN characterized by glomerular cell prolifera-
tion, including diffuse proliferative nephritis, IgA nephropathy,
lupus nephritis, and membranoproliferative GN [reviewed in
34]. In several experimental models of GN, monocyte-macro-
phage depletion with an anti-macrophage serum [35,361 or with
irradiation [371 resulted in a reduction in glomerular hypercel-
lularity, but it is unclear in these studies whether the decrease
in glomerular cellularity can be attributed to the reduction in
infiltrating monocytes, or if it is associated with a significant
Fig. 1. Involvement of platelets in subendothelial immune complex
nephritis. Ten minutes after induction of nephritis by renal artery
perfusion of concanavalin A (con A) and anti-con A antibody, numer-
ous platelets can be demonstrated in glomerular capillaries, often in
close association with the endothelium and basement membrane. Evi-
dence for platelet activation includes the centralization of granules
within platelets and the presence of filopodia. Key: C, capillary lumen;
p, platelet (x7IOO).
Fig. 2. A marked cell proliferation can be documented in glomeruli of
rats with subendothelial immune complex nephritis induced by the
perfusion of con A and anti-con A antibody. Shown is a glomerulus
from a rat two days after induction of GN, in which proliferating cells
can be identified by immunostaining for the proliferating cell nuclear
antigen (PCNA). Positive cells have a dark nuclear stain. (Immunoper-
oxidase with methyl green counterstain, x400).
decrease in endogenous glomerular cell number. However,
Matsumoto and Hatano have recently reported that macro-
phage depletion reduces the glomerular hypercellularity in a rat
model of anti-GBM nephritis, and that this treatment signifi-
cantly reduces the number of mesangial cells that can be
obtained from isolated glomeruli of these animals in culture
[38].
The potential mechanisms by which the macrophage medi-
ates glomerular cell proliferation could involve release by the
macrophage of growth factors [reviewed in 39] (Table 2), or
could involve stimulation by the macrophage of other cell types
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to release growth factors within the glomerulus. It is clear that
many growth factors present in macrophages, such as IL-I,
IL-6, PDGF, and TNF-a, mediate mesangial cell proliferation
in vitro (Table 1).
Endogenous glomerular cells
Although studies with glomerular endothelial cells have been
sparse due to the difficulty in establishing these cells in culture,
both endothelial cells from other sites and glomerular mesangial
cells secrete numerous growth factors [reviewed in 40, 41]
(Table 2). Many of the growth factors released by mesangial
cells, including PDGF, IL-I, IL-6, IGF-l, and TGF-f3, bind to
receptors present on the mesangial cell membrane, thus func-
tioning as autocrine growth factors [3, 6, 42, 43]. Consistent
with the hypothesis that mesangial cells may produce autocrine
growth factors in GN has been the observation that several
proliferative glomerular diseases in animals and humans are
associated with increased growth factor gene or protein expres-
sion in renal cortex or glomeruli [6, 44—47]. However, in many
of these studies, the possibility that the macrophage was
responsible for the increased expression of these factors was
not definitively excluded.
Platelet-derived growth factor
PDGF is a 30 kd molecular weight cationic protein consisting
of two disulfide-bonded chains existing as a heterodimer
(PDGF-AB) or as a homodimer (PDGF-AA or PDGF-BB)
[reviewed in 10]. The B-chain is almost identical to the trans-
forming protein of the Simian Sarcoma virus (p28sis), and is
coded by the c-sis proto-oncogene [10]. In platelets, PDGF is
stored in the alpha granules, from where it is released into the
extracellular environment following activation of the platelet by
numerous substances, including platelet activating factor,
thrombin, collagen, and immune complexes [reviewed in 48].
PDGF is also produced by many other cell types, including
renal microvascular endothelial cells, mesangial cells, macro-
phages, and smooth muscle cells [3, 10, 49].
PDGF may have an important role in mesangial cell prolifer-
ation. PDGF is a potent mitogen for mesenchymal cells in
culture [10], including mesangial cells [3]. Although some
studies suggest that PDGF may be a "complete" growth factor
for mesangial cells [3], others have reported that PDGF is a
"competence" factor, inducing cells to enter the cell cycle, as
opposed to "progression" factors which allow the cell to
complete the cell cycle once it has been initiated. Thus, PDGF
has been reported to make mesangial cells "competent" so that
they can further respond to IL-I [4] and IGF-l [50].
Recent studies also suggest that PDGF may have an addi-
tional role as an intermediary in mediating the effects of other
growth factors. A variety of growth factors, including EGF,
TNF-a, and bFGF will induce mesangial cells in culture to
produce PDGF and PDGF mRNA [51]. PDGF itself will also
induce mesangial cells to produce PDGF mRNA [51]. Most
importantly, the mitogenic effects of EGF on mesangial cells
[51] and of IL-I on fibroblasts [52] can be inhibited with
anti-PDGF antibody. This suggests that PDGF may have a
critical role as an autocrine growth factor for a variety of cell
types, including mesangial cells.
In contrast to mesangial cells, PDGF appears to have minimal
or no mitogenic effect for glomerular endothelial cells or epi-
thelial cells in culture [9], However, PDGF may have additional
effects besides being a mesangial cell mitogen. PDGF is a potent
chemotactic factor for smooth muscle cells [53] and mesangial
cells [54]. Recent studies suggest that the chemotactic proper-
ties of PDGF may play an important role in the smooth muscle
cell migration into the neointima that occurs in the rat carotid
following balloon angioplasty (Note added in proof, A).
Binding of PDGF to the cell membrane PDGF receptor
(PDGF-R) is dependent on the PDGF isoform. The PDGF
receptor consists of two subunits (a, j3) in which the a-subunit
can bind the A- or B-chain but the $-subunit only binds the
B-chain [55]. Thus, PDGF-R aa binds all forms of PDGF,
receptor aJ3 binds either PDGF-AB or PDGF-BB, and receptor
f3f3 binds only PDGF-BB [55]. Shortly after binding, the recep-
tor-ligand complex is endocytosed with loss of receptor expres-
sion on the cell surface [10]. Activation of tyrosine kinase leads
to autophosphorylation of the receptor as well as phosphoryla-
tion of cytoplasmic proteins [10]. Activation of phospholipase C
leads to generation of inositol triphosphate (1P3) which mobi-
lizes intracellular Ca2 and diacyiglycerol which activates pro-
tein kinase C, and this has been demonstrated in mesangial cells
[56, 57]. Within minutes to hours activation of the proto-
oncogenes c-myc and c-fos occurs [10], and additional poorly-
defined intracellular signaling eventually culminates in new
DNA synthesis.
Role of PDGF in GN
The observation that PDGF may be an important growth
factor for mesangial cells suggests that it may be involved in
glomerular diseases associated with mesangial cell prolifera-
tion, including lupus nephritis, IgA nephropathy, and membra-
noproliferative GN. Indeed, PDGF has been identified by
immunostaining in the glomerular capillary walls of some pa-
tients with diffuse proliferative lupus GN [58]. Recently, Gesu-
aldo et al have also reported that PDGF A- and B-chain
transcripts are increased in whole kidney RNA obtained from
mice with mesangial proliferative GN [461.
We have investigated whether PDGF is expressed in the
anti-Thy 1 model of mesangial proliferative nephritis in the rat
[58, 59]. A marked increase in PDGF A- and B-chain mRNA
could be documented in isolated glomerular RNA obtained
three and five days after inducing nephritis. The increased
expression of the PDGF mRNA occurred at the time of maxi-
mal mesangial cell proliferation, as documented by a 20-fold
increase in glomerular cells expressing the proliferating cell
nuclear antigen (PCNA) [58]. (PCNA is a nuclear protein that is
expressed from late Gl to the G2/M phase of the cell cycle [60]).
Cells expressing PDGF B-chain mRNA could also be docu-
mented in glomeruli by in situ hybridization using a digoxigenin-
labeled cRNA probe for the murine PDGF B-chain [59]. In
addition, cells expressing PDGF B-chain protein were identified
by immunostaining with the specific monoclonal antibody,
PGF-007 [58, 59]. Both complement depletion and platelet
depletion significantly reduced the cell proliferation and PDGF
expression.
The identity of the cells expressing PDGF was studied. Most
of the PDGF B-chain positive cells were in mesangial locations,
and by double immunolabeling >85% of the PDGF B-chain
positive cells were also positive for a-smooth muscle actin [58].
We have recently demonstrated that a-smooth muscle actin is
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expressed by mesangial cells in the Thy I model [1]. In addition,
macrophages and glomerular endothelial cells are negative for
this actin isoform by immunocytochemistry [lii. Therefore, this
study suggests that mesangial cells are the major source for the
increased PDGF expression in this model of nephritis, and thus
are consistent with Abboud's hypothesis [511 that PDGF may
function as a mesangial cell autocrine growth factor in glomer-
ular disease.
Further support for PDGF as an autocrine growth factor has
resulted from studies performed in our laboratory in the rem-
nant kidney (that is, 5/6 nephrectomy) model in the rat. In this
model, mesangial cell proliferation can be documented prior to
the development of glomerulosclerosis, and is associated with
increased glomerular mRNA and protein expression of the
PDGF B-chain (Note added in proof, B).
Mesangial proliferative nephritis may also be associated with
an up regulation of the PDGF-R. Recent studies have demon-
strated an increase in PDGF-Rf3 protein in mesangial areas of
patients with mesangial proliferative nephritis by immunostain-
ing [61]. We have examined the involvement of the PDGF-R in
the anti-Thy 1 model [58]. An 8- to 25-fold increase in PDGF-R/3
mRNA could be demonstrated in isolated glomerular RNA from
diseased rats by Northern analysis at three and five days
following induction of disease, The maximal expression of the
PDGF-R 13-subunit mRNA occurred at day 5 as opposed to that
for PDGF B-chain mRNA which occurred at day 3. By immu-
nostaining, the cells expressing the PDGF-R/3 appeared to be
mesangial cells. The up regulation of the PDGF-Rf3 could be
blocked if proliferation was inhibited by depleting rats of
complement or platelets. In contrast to the PDGF-R 13-subunit,
no PDGF-R a-subunit protein or mRNA could be detected in
normal or diseased glomeruli in this study. This suggests that
the mesangial cells may be interacting primarily with the
PDGF-BB isoform.
In conclusion, the mechanism of mesangial cell proliferation
in GN may likely involve the release of growth factors by both
exogenous (platelets and macrophages) and endogenous
(mesangial and endothelial) cells. Recent evidence supports the
hypothesis that PDGF may be one of the important growth
factors. In addition to being a growth factor that can be released
by activated platelets and macrophages, PDGF may also serve
as an autocrine growth factor for the mesangial cell. Studies are
currently underway to determine if inhibition of PDGF in vivo
can reduce the glomerular cell proliferation in mesangial prolif-
erative GN.
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